drugset / Trial / NCT00838877

Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid

NCT00838877 ↗

Phase 1 Completed 26 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The study is carried out in order to investigate if \[18F\]AZD4694, compared to \[11C\]AZD2184, is a suitable PET ligand for in vivo imaging of Aβ amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease. A whole body dosimetry scanning will be performed in 6 healthy volunteers to obtain human data to estimate a safe dose.

Timeline

Start
2009-01
Primary completion
—
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2184 Diagnostic / imaging agent — Intravenous
Subject AZD4694 Diagnostic / imaging agent — Intravenous

Indications